

AWARD NUMBER DAMD17-98-1-8118

TITLE: Characterization of Novel Breast Cancer Specific Gene, BCSG1, in Human Breast Cancer Progression

PRINCIPAL INVESTIGATOR: Yiliang Liu, Ph.D.

CONTRACTING ORGANIZATION: Long Island Jewish Medical Center  
New Hyde Park, New York 11040

REPORT DATE: July 2000

Type of report: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Port Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010925 199

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2000	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 99 - 30 Jun 00)	
4. TITLE AND SUBTITLE Characterization of Novel Breast Cancer Specific Gene, BCSG1, in Human Breast Cancer Progression			5. FUNDING NUMBERS DAMD17-98-1-8118	
6. AUTHOR(S) Yiliang Liu, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Long Island Jewish Medical Center New Hyde Park, New York 11040  E-MAIL: liu@lij.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)  <p style="text-align: center;"><b>SYNUCLEIN <math>\gamma</math> (SNCG) AND BREAST CANCER PROGRESSION.</b></p> <p>We recently identified and cloned a novel breast cancer-specific gene BCSG1 by direct differential cDNA sequencing. BCSG1 has a great sequence homology with Alzheimer disease (AD)-related neural protein synuclein, and thus was also named as synuclein <math>\gamma</math> (SNCG). We demonstrated that: 1) SNCG expression was a stage-specific in human breast: undetectable in normal or benign breast lesions, low level and partial expression in low grade ductal carcinoma <i>in situ</i> but extremely high level in advanced infiltrating breast cancer; 2) SNCG expression in human breast cancer cells is dramatically suppressed by tumor growth inhibitor oncostatin M (OM), a cytokine predominantly produced by activated T cells and macrophages; 3) overexpression of SNCG in breast cancer cells led to a significant increase in cell motility and invasiveness <i>in vitro</i> and a profound augmentation of metastasis <i>in vivo</i>. Our data suggest that the member of neural protein synucleins might have important functions outside the central nervous system and play a role in breast cancer progression.</p>				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 6	16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## TABLE OF CONTENTS

TABLE OF CONTENTS	3
BACKGROUND AND SIGNIFICANCE	4
WORK ACCOMPLISHED	4-5
TRAINING	5
REFERENCES	5-6

## I. BACKGROUND AND SIGNIFICANCE

Metastasis is proposed to depend on five major activities: angiogenesis, cellular attachment, proteolysis, migration through the barrier into the secondary sites, and, of course, colonization and proliferation in the distant organs. We have recently identified and cloned a putative breast cancer specific gene, BCSG1, which was (a) highly expressed in mammary gland relative to other organs and was (b) high abundance in a breast cancer cDNA library but scarcely in a normal breast cDNA library (1). We have demonstrated that expression of BCSG1 correlate with clinical aggressiveness and may indicate breast cancer malignant progression leading to metastasis. We also provided evidences linking overexpression of BCSG1 in human breast cancer cells with increased migratory motility and invasive activity *in vitro* and a profound augmentation of metastasis *in vivo* (2). The use of BCSG1 gene could be of importance in differentiating atypical proliferative breast lesions or noninvasive carcinoma *in situ* from malignant and invasive cancer and may be useful in screening of breast biopsies for potential abnormalities. In addition, if overexpression provides a therapeutic target, then BCSG1 may be useful in clinical management and treatment of breast cancer.

Interestingly, BCSG1 revealed no homology to any other known tumor metastasis related factors; rather, BCSG1 revealed extensive sequence homology to with Alzheimer disease (AD)-related neurotic proteins synuclein  $\alpha$  (SNCA) and synuclein  $\beta$  (SNCB) that are mainly localized to brain (3-9). Therefore, BCSG1 was also named as synuclein  $\gamma$  (SNCG). The pathological hallmark of AD is amyloid deposition in neurotic plaques and blood vessels. The major constituent of amyloid is a 39-43 AA peptide named A $\beta$  component and SNCA is the second intrinsic constituent of amyloid. An elucidation of the reasons for SNCG overexpression in infiltrating breast cancer and SNCG-induced metastasis may shed some light on the pathogenesis of not only breast cancer progression but also neurodegenerative disorders.

## II. WORK ACCOMPLISHED

The overall hypothesis to be evaluated is that up-regulation of BCSG1/SNCG expression may indicate breast cancer malignant progression from a benign breast or a low grade *in situ* carcinoma and to a highly infiltrating carcinoma. The overexpression of BCSG1 may correlate with clinical aggressiveness of breast cancers. Therefore an alternations of BCSG1 expression may lead to an abnormal growth and malignant progression.

Overexpression of SNCG in breast cancer cells led to a significant increase in motility and invasiveness *in vitro* and a profound augmentation metastasis *in vivo* (2). This is the first report indicating the potential involvement of synuclein in the non-neurotic disease. An elucidation of the reasons for SNCG overexpression in infiltrating breast cancer and SNCG-induced metastasis may shed some light on the pathogenesis of not only breast cancer progression but also neurodegenerative disorders. Please see attached paper for detail description.

Previously, we have shown that synuclein  $\gamma$  (SNCG), a member of the brain protein synuclein family, is highly expressed in human infiltrating breast carcinomas but not expressed in normal or benign breast tissues. The SNCG mRNA was also detected in several human breast cancer cell lines with the highest expression found in H3922, a cell line derived from an infiltrating ductal carcinoma. In this study, we show that expression of SNCG mRNA in H3922 cells is significantly decreased by treating cells with the cytokine oncostatin M (OM) who has a growth-inhibitory effect on these cells (10). A decrease in SNCG mRNA level can be detected as early as 30 min after OM addition. By 4 h OM treatment, the level of SNCG mRNA was decreased to 70%

of control, and by 24 h the mRNA was below undetectable level. Since OM-induced growth inhibition occurs after 2 to 3-days, the down-regulation of SNCG expression appears to proceed the effect of OM on cell growth. Additional experiments to measure the transcriptional rates of SNCG indicate that the observed OM-induced down-regulation of SNCG mRNA occurs mainly at the transcriptional level. In an attempt to examine the role of SNCG gene in the proliferation of breast cancer cells, SNCG cDNA was stably transfected into MCF-7 cells that do not express endogenous SNCG gene. Examination of cell growth under anchorage-dependent and anchorage-independent conditions demonstrates that over expression of SNCG gene significantly stimulated the growth of MCF-7 cells both in monolayer culture and in soft agar. These data together suggest that SNCG may be one of the contributing factors that promote the uncontrolled growth of malignant mammary cells.

### III. TRAINING

This is PI's first independent grant. The proposed studies of the current grant application includes a variety of different aims and experiments ranging from basic molecular biology, cell biology, in vivo orthotopic nude mice model for tumor growth and metastasis, and a clinical oriented study on screening clinical human breast specimens. This is the first time that PI has a chance to independently carry out a very challenge, yet ambitious, multi display project. During the last year, PI has gained a lot of experience on animal model and in vivo analysis of tumor metastasis. The success on the current grant proposal will encourage and facilitate PI's future career development as an independent clinically oriented breast cancer investigator.

### IV. REFERENCES

1. Ji, H., Liu, Y. E., Jia, T., Wang, M., Liu, J., Xiao, G., Joseph, B. K., Rosen, C. and Shi, Y. E. Identification of a breast cancer-specific gene, BCSG1, by direct differential complementary DNA sequencing. *Cancer Res.*, 57: 759-764, 1997.
2. Tongli Jia, Jingwen Liu, Yiliang E. Liu and Y. Eric Shi. Stimulation of breast cancer invasion and metastasis by synuclein  $\gamma$  (SNCG). *Cancer Res.* 59: 742-747, 1999.
3. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y. and Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc. Natl. Acad. Sci. U.S.A.*, 90(23): 11282-6 1993.
4. Xia, Y., Rohan-de-Silva, H. A., Rosi, B. L., Yamaoka, L. H., Rimmler, J. B., Pericak-Vance, M. A., Ross, A. D., Chen, X., Masliah, E., DeTeresa, R., Iwai, A., Sundsmo, M., Thomas, R. G., Hofstetter, C. R., Gregory, E., Hansen, L. A., Katzman, R., Thal, L. J. and Saitoh, T. Genetic studies in Alzheimer's disease with an NACP/a-Synuclein polymorphism. *Ann. Neurol.*, 40: 207-215, 1996.
5. Jakes, R., Spillantini, Maria Grazia and Goedert, Michel. Identification of two distinct synucleins from human brain. *FEBS Letters*, 345: 27-34, 1994.
6. Spillantini, M. G., Schmidt, M.L., Lee, V.M., Trojanowski, J. Q., Jakes, R. and Goedert, M.  $\alpha$  - Synuclein in Lewy bodies. *Nature*, 388: 839-840, 1997.
7. Masters, C. L., Simms, G., Wenman, N.A., Multhup, G., McDonald, B. L. and Beyreuther, K. Amyloid plaque core in Alzheimer's disease and Down syndrome. *Proc. Natl. Acad. Sci. USA*, 82: 4245-4249, 1985.
8. Clayton, D. F. and George, J. M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci.*, 21(6): 249-254, 1998.

9. Takeda, A., Mallory, M., Sundsmo, M., Honer W., Hansen, L. and Masliah, E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. *J. Pathol.*, 152(2): 367-372, 1998.
10. Jingwen Liu, Michael J. Spence, Y. Lynda Zhang, Yangfu Jiang, Yiliang E. Liu, and Y. Eric Shi. Transcriptional suppression of synuclein  $\gamma$  (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. *Breast Cancer Research and Treatment*. Submitted